1. Home
  2. TGE vs ACET Comparison

TGE vs ACET Comparison

Compare TGE & ACET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

TGE

The Generation Essentials Group Class A Ordinary Shares

N/A

Current Price

$1.45

Market Cap

66.4M

ML Signal

N/A

Logo Adicet Bio Inc.

ACET

Adicet Bio Inc.

HOLD

Current Price

$8.19

Market Cap

71.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TGE
ACET
Founded
2023
1947
Country
France
United States
Employees
N/A
N/A
Industry
Newspapers/Magazines
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
66.4M
71.3M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
TGE
ACET
Price
$1.45
$8.19
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$96.67
AVG Volume (30 Days)
145.2K
199.8K
Earning Date
10-20-2025
03-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.48
N/A
Revenue
$130,212,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$3.03
N/A
Revenue Growth
316.50
N/A
52 Week Low
$0.78
$7.15
52 Week High
$37.02
$17.44

Technical Indicators

Market Signals
Indicator
TGE
ACET
Relative Strength Index (RSI) N/A 79.68
Support Level N/A $7.70
Resistance Level N/A $8.56
Average True Range (ATR) 0.00 0.50
MACD 0.00 0.08
Stochastic Oscillator 0.00 90.54

Price Performance

Historical Comparison
TGE
ACET

About TGE The Generation Essentials Group Class A Ordinary Shares

The Generation Essentials Group is a media and entertainment company. Its publications L'Officiel and The Art Newspaper publish print editions in a total of nearly 28 countries and territories and digital contents. It operate in the movie production sector having produced various Asia-focused movies. It operate in three operating segments: media and entertainment segment, hotel operations, hospitality and VIP services segment and strategic investment segment. Key revenue is generated from strategic investment segment that is engage in proprietary investments and management of portfolio, including listed and unlisted equity shares investments and movie income right investments.

About ACET Adicet Bio Inc.

Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.

Share on Social Networks: